Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer
Latest Information Update: 16 Mar 2023
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IFCT-1103 ULTIMATE; Ultimate
- 07 Apr 2020 Primary endpoint has been met.
- 07 Apr 2020 Results published in the European Journal of Cancer
- 25 May 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2012-004524-38).